ManageChatDiscover
301252

SHORT AND LONG TERM CARDIOTOXICITY OF SOFOSBUVIR AND DACLATASVIR ASSOCIATED WITH LIPID PROFILE ABNORMALITIES

Article

Last updated: 04 Jan 2025

OverviewSimilar Items

Subjects

-

Tags

-

Abstract

Background: Direct-acting antivirals (DAA) are relatively a new group of drugs. Different studies reported disturbances in lipid metabolism among HCV patients treated with DAA combinations Objective: This study tries to evaluate the short and long term effects of DDA on lipid profile, cardiac enzymes and oxidative stress, as well as, to determine if these effects are disease-related or drug-dependent.  Methods: Male Wistar rats were treated with sofosbuvir with or without daclatasvir for four consecutive weeks. Five samples were collected at day 0 (baseline point), another ten samples were obtained after four weeks (end of treatment point) and finally, after six months of treatment, the last ten animals were assigned for follow up point. AST, ALT, lipid profile, serum creatine kinase and troponin were assessed colorimetrically. Moreover, liver tissue content of malondialdehyde was assessed. Results: Results revealed that, at the end of drug therapy period, sofosbuvir whether alone or combined with daclatasvir caused significant increase in total cholesterol, LDL and triglyceride compared to baseline data. These effects were persistent for 20 weeks after the end of treatments. This increase in lipid profile was also correlated with a significant deterioration of cardiac markers such as troponin and creatine kinase –MB and increased oxidative stress. Conclusion: Sofosbuvir and/or daclatasvir elevate lipid profile and cardiac enzymes. These changes are due to the effects of direct acting antiviral agents and independent of hepatitis C virus infection. Consequently, Lipid profile and cardiovascular markers should be monitored during and after drug cessation.

DOI

10.21608/bfsa.2023.301252

Keywords

Sofosbuvir, Daclatasvir, Lipid profile, troponin, CK-MB - MDA

Authors

First Name

Sherin

Last Name

Zakaria

MiddleName

-

Affiliation

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt

Email

sherin_zakaria@pharm.kfs.edu.eg

City

-

Orcid

0000-0002-8448-9901

First Name

Shady

Last Name

Allam

MiddleName

-

Affiliation

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Menoufia University, Menoufia, Egypt

Email

shady.allam@pharm.kfs.edu.eg

City

-

Orcid

0000-0002-5633-4128

First Name

Alaa

Last Name

El-Sisi

MiddleName

E.

Affiliation

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tanta University, Tanta, Egypt

Email

alaa.elsayed2@pharm.tanta.edu.eg

City

-

Orcid

-

Volume

46

Article Issue

1

Related Issue

41495

Issue Date

2023-06-01

Receive Date

2022-09-19

Publish Date

2023-06-01

Page Start

551

Page End

563

Print ISSN

1110-0052

Online ISSN

3009-7703

Article File

BFSA_Volume 46_Issue 1_Pages 551-563.pdf

PDF . 1.4MB

Link

https://bpsa.journals.ekb.eg/article_301252.html

Detail API

https://bpsa.journals.ekb.eg/service?article_code=301252

Order

301,252

Type

Original Article

Type Code

1,096

Publication Type

Journal

Publication Title

Bulletin of Pharmaceutical Sciences Assiut University

Publication Link

https://bpsa.journals.ekb.eg/

MainTitle

SHORT AND LONG TERM CARDIOTOXICITY OF SOFOSBUVIR AND DACLATASVIR ASSOCIATED WITH LIPID PROFILE ABNORMALITIES

Details

Type

Article

Created At

25 Dec 2024